Our Pipeline

BioMendics is committed to advancing its small molecule liquid crystal MTORX Technology to develop life-enhancing medicines for people suffering from epidermolysis bullosa, epidermolytic ichthyosis, pachyonychia congenita, and other rare dermatologic disorders.

BM-3103
INDICATION IP ENABLED Preclinical IND PHASE 1 PHASE 2 PHASE 3
Epidermolysis Bullosa Simplex
Epidermolysis lchthyosis
Pachyonychia Congenita
Scleroderma
eb